Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Dividend Champion Spotlight: Aflac Incorporated

2018-07-05 seekingalpha
Aflac operates with a negative cost of float - a strong indicator of a well run insurance company.
AFL 8686 AFSD

34
Aflac Enters Oversold Territory

2018-06-27 zacks
Aflac Incorporated (AFL - Free Report) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at AFL given that, according to its RSI reading of 28.94, it is now in oversold territory.
AFL 8686 AFSD

34
Avoid Reinsurance Group, Add These Top 4 Insurance Stocks

2018-06-20 zacks
Reinsurance Group of America, Incorporated (RGA - Free Report) has been witnessing southbound revisions of late. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 7.3% downward while for 2019, the consensus mark moved nearly 0.4% south. The stock carries a Zacks Rank #4 (Sell) with an unimpressive VGM Score of C. Back tested results show that stocks with a favorable VGM Score of A or B when combined with a bullish Zacks Rank #1 (Strong Buy) or 2 (Buy), comfortably outperform other stocks.
AFL RGA PGR NAVG 8686 AFSD

47
Avoid Cincinnati Financial, Add These Top 4 Insurance Stocks

2018-06-15 zacks
Cincinnati Financial Corporation (CINF - Free Report) has been witnessing southbound revisions of late. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 10.1% downward while for 2019, the consensus mark moved nearly 5.8% south. The stock carries a Zacks Rank #5 (Strong Sell) with an unimpressive VGM Score of D. Back tested results show that stocks with a favorable VGM Score of A or B when combined with a bullish Zacks Rank #1 (Strong Buy) or 2 (Buy), comfortably outperform other stocks.
AFL KMPR SPG.PRJ KMPA CINF PGR SPG 8686 AFSD

54
6-Year High Inflation Reinforces June Rate Hike: 5 Top Picks

2018-06-13 zacks
The U.S. Federal Reserve will likely lift the benchmark interest rate this week, to stay a step ahead of inflation. Yesterday’s Labor Department report revealed that U.S. consumer prices in May had logged its biggest gain in the last six years. The U.S. economy is at its full employment level and a stretched workforce market will eventually push up inflation; as employers are trying to brave labor shortages with higher wages.
NCBS AFL KMPR KMPA XOM OSBC 8686 AFSD AB

79
6 Dividend Aristocrats to Buy as Trump Irks G7

2018-06-11 investorplace
The U.S.-Canada trade dispute escalated after U.S. President Donald Trump called Canadian Prime Minister Justin Trudeau “very dishonest and weak.” Trump had accused Canada of “charging massive tariffs” to U.S. businesses.
ROP CTAS AFL PX GWW ADPVV ADP 8686 AFSD

80
6 Dividend Aristocrats to Buy as Trump Irks G7

2018-06-11 zacks
The U.S.-Canada trade dispute escalated after U.S. President Donald Trump called Canadian Prime Minister Justin Trudeau “very dishonest and weak.” Trump had accused Canada of “charging massive tariffs” to U.S. businesses.
ROP XEL CTAS AFL HSC GWW PX ADPVV ADP 8686 AFSD

78
7 Dividend Aristocrats That Could Outpace the Market | InvestorPlace

2018-05-23 investorplace
Seasoned dividend investors know that there are big differences between stocks that pay dividends and companies that legitimately have “dividend stocks.” Companies in the latter category have, in many cases, displayed lengthy commitments to not only paying dividends but growing payouts as well.
SPGI PG AFL XOM KO 8686 AFSD CLX MDT

34
Aflac: Excellent Management Offers 50% Upside

2018-05-17 seekingalpha
Market doesn't understand the economic characteristics of these investable funds and is therefore affording a low valuation than is warranted.
AFL 8686 AFSD

117
AIG Q1 Earnings Miss Estimates & Fall Y/Y, Shares Decline

2018-05-03 zacks
American International Group Inc. (AIG - Free Report) reported first-quarter 2018 operating earnings of $1.04 per share that missed the Zacks Consensus Estimate by 16%. In the year-ago quarter, the company had reported earnings of $1.36 per share.
TMK AVF TMK AIG TMK.PRC AFL AIG.WS TMK.PRB UBS UBS.PRDCL 8686 AFSD GNW 8685 ULSGF

53
Lincoln National (LNC) Q1 Earnings Beat Estimates, Up YoY

2018-05-03 zacks
Lincoln National Corporation’s (LNC - Free Report) first-quarter 2018 earnings of $1.97 per share surpassed the Zacks Consensus Estimate by 1.6%. Also, the bottom line increased about 3% year over year, led by higher fee income.
TMK LNC.WS TMK LNC TMK.PRC AFL TMK.PRB UBS UBS.PRDCL 8686 AFSD GNW ULSGF

34
Aflac's Q1 2018: I'm Sleeping Well With My Shares

2018-05-03 seekingalpha
As expected, the net profit grew, boosted by the lower corporate tax in the U.S. and a favorable yen/dollar exchange rate.
AFL 8686 AFSD

67
Unum Group (UNM) Q1 Earnings Miss Estimates, Revenues Beat

2018-05-02 zacks
Unum Group’s (UNM - Free Report) first-quarter 2018 operating net income of $1.24 per share missed the Zacks Consensus Estimate by 0.8%. The bottom line however improved 19.2% year over year on higher premiums and stable benefits experience. Moreover, lower tax rate provided an additional boost to the metric.
UNM WFC WFCNP WFC.WS WFC.PRL WFC.PRJ WFC.PRT EIG WFC.PRR WFC.PRQ AFL WFC.PRP WFC.PRO WFC.PRN AMSF 8686 WFC.PRY AFSD WFC.PRX WFC.PRW WFC.PRV

219
8 Dividend Aristocrats That Also Offer Stock Price Growth | InvestorPlace

2018-04-30 investorplace
Many investors are drawn to the consistency of dividend aristocrats. These stocks, called “aristocrats” because they have increased their dividend every year for at least 25 years, have earned the confidence of income-oriented investors, many of whom trade the prospect of growth for the steady payout. Moreover, the increases perpetuate themselves, as no corporate management team wants to end a decades-long streak of dividend growth.
LOW HD GD XOM WMT TGT AMZN AFL JNJ CVX ITW MSFT 8686 AFSD MCD

50
Amerisafe (AMSF) Q1 Earnings Top Estimates on Lower Expenses

2018-04-27 zacks
Amerisafe Inc. (AMSF - Free Report) reported first-quarter 2018 operating earnings per share of 86 cents, beating the Zacks Consensus Estimate by 17.8%. Earnings were up 21% year over year.
UNM EIG EMN.WS AFL EMN AMSF CLD CLDEP 8686 AFSD

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 001055902